[ad_1] The coronal view of a human brain of a patient suffering from Parkinson’s disease Sherbrooke Connectivity Imaging Lab | Getty Images A highly popular class of drugs for diabetes and obesity is showing early potential to help patients with Parkinson’s disease, too. An older diabetes treatment called lixisenatide helped slow the progression of motor…
[ad_1] The German share price index DAX graph is pictured at the stock exchange in Frankfurt, Germany, January 19, 2024. Staff | Reuters Over the last 12 months, just 11 stocks made up half of the gains that powered the pan-European Stoxx 600 stock index to a record-high close on Friday. Earlier this month, Goldman…
[ad_1] Sen. Bernie Sanders, I-Vt., holds his news conference with Sen. Ed Markey, D-Mass., in the Capitol on Thursday, January 25, 2024, on issuing subpoenas for pharmaceutical company CEOs to testify regarding drug prices. Bill Clark | Cq-roll Call, Inc. | Getty Images The CEOs of Merck and Johnson & Johnson have voluntarily agreed to…
[ad_1] Still life of Wegovy an injectable prescription weight loss medicine that has helped people with obesity. It should be used with a weight loss plan and physical activity. Michael Siluk | UCG | Getty Images Drugmakers have been scrambling to join a two-horse race to lead the market for popular weight loss drugs, which…
[ad_1] Medical personnel use a mammogram to examine a woman’s breast for breast cancer. Hannibal Hanschke | dpa | Picture Alliance | Getty Images SAN FRANCISCO — An established but promising group of cancer drugs was a red-hot market in 2023, and more companies could look to the treatments to fuel growth in the year…
[ad_1] Investors are contemplating where and when the next big obesity drug deal will occur. At the moment, Novo Nordisk and Eli Lilly have the growing obesity drug market all to themselves. But given the potential size of this opportunity, which some have put at more than $100 billion by 2030 , other pharmaceuticals companies…
[ad_1] Sopa Images | Lightrocket | Getty Images Pfizer’s twice-daily version of its experimental weight loss pill has now joined a long list of other scrapped drugs that aimed to treat obesity but came with unintended consequences. The drugmaker on Friday said it will stop developing the twice-daily treatment, danuglipron, after obese patients taking the…
[ad_1] A RSV-infected child receives treatment, as RS-Virus infections spread among children at Missio children’s clinic Moenchberg, in Wuerzburg, Germany, December 2, 2022. Heiko Becker | Reuters The Centers for Disease Control and Prevention expedited the release of more than 77,000 additional doses of a new drug designed to protect infants from respiratory syncytial virus…
[ad_1] Sanofi Lantus brand insulin pens are arranged for a photograph in the Brooklyn borough of New York, U.S., on Friday, April 5, 2019. Alex Flynn | Bloomberg | Getty Images Americans, regardless of their insurance status, can now access Sanofi‘s most widely prescribed insulin for $35 through the prescription drug savings company GoodRx, the…
[ad_1] A doctor vaccinates an infant against respiratory syncytial virus (RSV) in a treatment room of her paediatric practice. Swen Pförtner | Picture Alliance | Getty Images Two new immunizations promise to protect babies from respiratory syncytial virus – if people can find them. Providers are scrambling to offer Pfizer’s vaccine, Abrysvo, to pregnant patients…
